Ustekinumab for treating ulcerative colitis: an expert opinion

Livia Biancone, Sandro Ardizzone, Alessandro Armuzzi, Fabiana Castiglione, Renata D’Incà, Silvio Danese, Marco Daperno, Paolo Gionchetti, Fernando Rizzello, Maria Lia Scribano, Maurizio Vecchi, Ambrogio Orlando

Research output: Contribution to journalArticlepeer-review


Introduction: Biologic agents have revolutionized the therapeutic management of ulcerative colitis. Anti-tumor necrosis factor agents were the first biologic drugs used to induce and maintain remission in this inflammatory bowel disease. Recently, another biologic option, ustekinumab, has become available for the treatment of moderate-to-severe ulcerative colitis. Areas covered: In this article, the authors review the literature on the efficacy and safety of ustekinumab in the context of current biologic agents used for the management of this disease. The potential role of ustekinumab in the treatment paradigm of the disease is also discussed. Expert opinion: The UNIFI trial has demonstrated the efficacy and safety of ustekinumab in induction and maintenance phases of treatment for ulcerative colitis. Ustekinumab may provide clinical benefit in a range of settings in patients with ulcerative colitis, even for those with multiple treatment failures, which are relatively common in daily clinical practice. Future clinical trials should compare the efficacy of ustekinumab with existing biologic agents in the management of ulcerative colitis.
Original languageEnglish
Pages (from-to)1321-1329
Number of pages9
JournalExpert Opinion on Biological Therapy
Issue number11
Publication statusPublished - 2020


  • inflammatory bowel disease
  • Interleukin 12/23 inhibitor
  • ulcerative colitis
  • ustekinumab


Dive into the research topics of 'Ustekinumab for treating ulcerative colitis: an expert opinion'. Together they form a unique fingerprint.

Cite this